Evaluating the effectiveness of darbepoetin alfa 300 mcg Q3W for the treatment of chemotherapy-induced anemia
Ralph V. Boccia(Center for Cancer and Blood Disorders), G. Otterson(Amgen (United States)), Peter T. Silberstein(CHI Health Creighton University Medical Center - Bergan Mercy), Charles Holladay(Amgen (United States)), D. Liu(Amgen (United States)), Giuseppe Rossi(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Dianne Tomita, N. Simon Tchekmedyian(Amgen (United States))
Cited by 7
Related Papers
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
|European Journal of Cancer|1993|545